You are now leaving the pages of www.gilead.com intended for U.S. audiences. The information in this section is intended for visitors outside the United States.
Gilead to Repatriate Funds to the United States
Dr. George P. Shultz Resigns from Gilead Sciences Board of Directors
John W. Madigan Joins Gilead Sciences Board of Directors
Data Show Efficacy of Standard Dosing Regimen of AmBisome(R) is Similar to High Loading Dose for Patients with Invasive Fungal Infections
Gilead Launches an Educational Website on Advances in Combination Therapy For HIV
Gilead Sciences to Present at the NASDAQ 16th Investor Program on Thursday, December 8th; Webcast Available Through Gilead Corporate Website
Gilead Sciences to Present at the Lazard Capital Markets Life Sciences Conference on Wednesday, November 30th; Webcast Available Through Gilead Corporate Website
Preliminary 24-Week Data Evaluating the Impact of Switching from Twice-Daily Combivir(R) to Once-Daily Truvada(R) in Patients with HIV Presented at 10th European AIDS Conference
Gilead and Roche End Tamiflu(R) Dispute; Expanded Collaboration Includes Gilead Role in Oversight of Manufacturing and Commercialization
Five-Year Data Evaluating Long-Term Therapy with Hepsera(R) for Hepatitis B ''e'' Antigen-Negative Chronic Hepatitis B Presented at AASLD Annual Meeting
Gilead Sciences to Present at the Credit Suisse First Boston Healthcare Conference on Thursday, November 17th; Webcast Available Through Gilead Corporate Website
Gilead Sciences to Present at the CIBC World Markets 16th Annual Healthcare Conference on Monday, November 7th; Webcast Available Through Gilead Corporate Website
Gilead Sciences Announces Third Quarter 2005 Financial Results
Gilead Sciences to Release Third Quarter 2005 Financial Results on Tuesday, October 18, 2005; Conference Call and Webcast to Follow
Gilead Sciences to Present at the 2005 UBS Global Life Sciences Conference on Tuesday, September 27th; Webcast Available Through Gilead Corporate Website
Gilead Sciences to Present at Two Upcoming Investor Conferences
Gilead Reduces Prices for Viread(R) and Truvada(R) in the Developing World
Gilead Sciences' Board Member Amends Existing Rule 10b5-1 Stock Trading Plan
Gilead and Achillion Announce Initiation of Phase I Clinical Trial Evaluating GS 9132 for the Treatment of Hepatitis C
Gilead Provides Update on Development of Fixed-Dose Regimen of Truvada(R) (Emtricitabine and Tenofovir Disoproxil Fumarate) and Sustiva(R) (Efavirenz)
Gilead Sciences Announces Management Promotions
John F. Cogan Joins Gilead Sciences Board of Directors
Gilead Sciences and Royalty Pharma Complete $525 Million Purchase from Emory University of Emtricitabine Royalty Interest
Gilead Sciences Announces Initiation of Phase III Clinical Program Evaluating Tenofovir Disoproxil Fumarate for the Treatment of Chronic Hepatitis B Virus
Gilead Sciences Announces Second Quarter 2005 Financial Results
Gilead Sciences and Royalty Pharma Announce $525 Million Agreement with Emory University to Purchase Royalty Interest for Emtricitabine
Gilead Sciences to Release Second Quarter 2005 Financial Results on Tuesday, July 19, 2005; Conference Call and Webcast to Follow
Data Evaluating Long-Term Therapy with Hepsera for Hepatitis B ''e'' Antigen-Negative Chronic Hepatitis B Published in the New England Journal of Medicine
Gilead Delivers Termination Notice to Roche for Tamiflu Development and Licensing Agreement
Gilead Announces Initiation of Phase I/II Clinical Trial Evaluating HIV Integrase Inhibitor GS 9137
Gilead Sciences to Present at the Goldman Sachs 26th Annual Global Healthcare Conference on Wednesday, June 15th; Webcast Available Through Gilead Corporate Website
Gilead Sciences to Present at the Banc of America Securities Health Care Conference 2005 on Tuesday, May 17th; Webcast Available Through Gilead Corporate Website
Gilead Sciences' Board Member Establishes Rule 10b5-1 Stock Trading Plan
Gilead Provides Update on Development of Fixed-Dose Regimen of Truvada -emtricitabine and tenofovir disoproxil fumarate- and Sustiva -efavirenz-
Gilead Sciences and Aspen Pharmacare Sign Letter of Intent to Establish Non-Exclusive Licensing and Distribution Agreement for Antiretrovirals Truvada and Viread in Developing World Countries
Gilead Sciences Announces First Quarter 2005 Financial Results
Gilead Sciences to Release First Quarter 2005 Financial Results on Tuesday, April 19, 2005; Conference Call and Webcast to Follow
Gilead Sciences Announces Early Termination of Hart-Scott-Rodino Waiting Period for the Japan Tobacco License for JTK-303
Gilead and Japan Tobacco Sign Licensing Agreement for Novel HIV Integrase Inhibitor
Gilead Expands Global Access Program for HIV Therapies to Include Additional Countries in the Caribbean and Latin America; Bahamas Manufacturing Plant Established
Gilead Sciences to Present at the SG Cowen & Co. 25th Annual Health Care Conference on Tuesday, March 15th; Webcast Available Through Gilead Corporate Website
48-Week Data Comparing Viread Versus Abacavir as Replacement for Thymidine Analogue in Lipoatraphic HIV Patients Presented at the 12th Conference on Retroviruses and Opportunistic Infections
European Commission Approves Truvada, a Once-a-Day Tablet Containing Gilead Sciences' Anti-HIV Drugs Emtriva and Viread
Gilead Sciences to Present at the Merrill Lynch Global Pharmaceutical, Medical Device, and Biotechnology Conference on Tuesday, February 8th
Gilead Announces Preliminary 48-Week Data From Study 934 Comparing Viread and Emtriva to Combivir Both in Combination With Sustiva in Patients With HIV
Gilead Sciences Announces Fourth Quarter and Full Year 2004 Financial Results
Gilead Sciences to Release Fourth Quarter and Year End 2004 Financial Results on Thursday, January 27, 2005; Conference Call and Webcast to Follow
Gilead Sciences to Present at the 23rd Annual JPMorgan Healthcare Conference on Monday, January 10th; Webcast Available Through Gilead Corporate Website
2012 Interactive Annual Report